The graveyard
Channels die. The advertising for them does not. These are the offers we used to be able to price, what happened to each, and where the thing you were looking for went.
Gone#
Apostrophe — Teledermatology subscription — prescription skincare by mail, owned by Hims & Hers.
Hims & Hers closed the brand and cancelled subscriptions.
Still advertised? Yes — stale affiliate listings and review roundups for it still circulate, which is why it stays in our records rather than being deleted from them.
Source: BeautyMatter · The prescription-skincare market, priced →
Hims compounded GLP-1s — Compounded semaglutide at Hims, including the $49/day compounded oral semaglutide offer.
Novo Nordisk and Hims & Hers settled, and Hims exited compounded GLP-1s. The company still operates and still sells weight-loss medication — brand product at manufacturer-matching prices, plus its membership — so this is an offer that died rather than a company.
Still advertised? The $49/day figure still appears in older comparison content. It is not purchasable.
Source: CNBC · What Hims sells now, priced →
503B bulk compounded GLP-1s — Semaglutide and tirzepatide compounded in bulk by FDA-registered outsourcing facilities and sold through telehealth, historically $99–299 a month.
FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List. Bulk compounding of these drugs is over outside a declared shortage. Patient-specific 503A compounding is a separate legal route and continues.
Still advertised? The old bulk-era prices anchor a lot of expectations. Anything advertising them today is either 503A compounding, which is priced differently, or not what it claims.
Source: FDA · What legal compounding looks like now →
Advertised, but we could not confirm it exists#
A different category, and worth separating. Nothing here is an accusation that a company is fake — it is a record that we went looking for a primary source, could not find one, and therefore will not publish a price. Under our own rule that every figure needs a source, that is the only available outcome. If one of these turns out to have a real, checkable price page, tell us and it goes in the index.
Embody — A GLP-1 brand that appears in advertorial content and 'best of' roundups.
We tried to add it to the index and could not. Its research trail is advertorial-only with no stable price page, and no GLP-1 site resolves at any plausible domain we tried — embody.com, embodyhealth.com, joinembody.com, tryembody.com and embodyrx.com are all dead, and getembody.com is a parked domain-for-sale page.
Still advertised? Yes. That is the entire reason this entry exists.
Our own checks — there is no source to cite, which is the finding · Every channel we can actually verify →
Changed hands, still trading#
Not dead, and listed here only so an acquisition headline does not get mistaken for a closure notice.
Lemonaid Health — Sold to Bambu Ventures/Innova for $10M in the 23andMe wind-down on 2025-09-19. Still operating, and still the only channel we track with an explicit one-time consult fee ($25, covering 12 refills) rather than a subscription.
Source: HLTH · Lemonaid, priced →
What this says about the market#
Of the three dead entries above, one closed by its owner, one withdrawn after litigation, one ended by a federal rule — not one of them failed because customers left. That is the useful pattern: in this market the thing you bought can disappear for reasons that have nothing to do with you, on a timeline nobody announces in advance.
It is also the strongest argument against paying for a year up front. We track 17 active channels. Setting aside the manufacturer-direct programmes — whose parent companies are not going anywhere — three of the 14 independent sellers we have a founding year for are two years old or younger: Direct Meds, Cora, Trimi. The break-even arithmetic on prepaid plans assumes the provider is still selling the thing in month nine.
Common questions#
What happened to Apostrophe?#
Hims & Hers closed the brand and cancelled subscriptions. That was on 2025-03-07. Affiliate listings and review roundups for it still circulate, which is why a search can still lead you to it.
Why did Hims stop selling compounded semaglutide?#
Novo Nordisk and Hims & Hers settled, and Hims exited compounded GLP-1s. The company still operates and still sells weight-loss medication — brand product at manufacturer-matching prices, plus its membership — so this is an offer that died rather than a company. The $49/day compounded oral semaglutide price still appears in older comparison content and is not purchasable.
Is Embody a real GLP-1 provider?#
We could not confirm that it is. We tried to add it to the index and could not. Its research trail is advertorial-only with no stable price page, and no GLP-1 site resolves at any plausible domain we tried — embody.com, embodyhealth.com, joinembody.com, tryembody.com and embodyrx.com are all dead, and getembody.com is a parked domain-for-sale page. We do not list prices we cannot source, so it is not in our index — but it is still advertised, which is why we say so here rather than staying silent.
Pricing journalism, not medical advice. Historical prices are recorded as they were published at the time and are not purchasable. An entry here is a record of what we could and could not verify on the dates shown, not a claim about any company's current conduct — disclosure.